A multicentre observational study of changes in clinical factors associated with the administration of immune checkpoint inhibitors in gastrointestinal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050220135

Enrollment

280

Registered

2022-12-16

Start date

2022-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer, oesophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases used Nivolumab/Pembrolizumab for unresectable or recurrent gastric and oesophageal cancer from October 2017 to December 2024

Exclusion criteria

Exclusion criteria: Cases in which treatment was terminated before the start of the second course Cases where blood tests were not done before the start of the second course

Design outcomes

Primary

Measure	Time frame
Progression free survival, Overall survival	—

Contacts

Public ContactHiroto Inoue

Shiga University of Medical Science

inohiro@belle.shiga-med.ac.jp+81-77-548-2217

Outcome results